FDA Grants Expanded Approval for ImmunityBio's Anktiva Bladder Cancer Drug

Key Facts

1ImmunityBio's drug Anktiva has received an expanded approval from the US FDA for the treatment of bladder cancer.

ImmunityBio's drug Anktiva has received an expanded approval from the US FDA for the treatment of bladder cancer. Reuters reported that the approval specifically targets non-muscle invasive bladder cancer that is unresponsive to BCG treatment, following clinical evaluations that demonstrated the drug's efficacy in a broader patient population.

IBRX closed at $9.8 on October 13, 2026, with the stock reaching a day high of $10.06 and a low of $9.56 during that session. This regulatory milestone is expected to increase the addressable market for ImmunityBio within the biotechnology and cancer treatment segments.